Compounds > glutamine

glutamine and gemcitabine

glutamine has been researched along with gemcitabine in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (33.33)24.3611
2020's6 (66.67)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Cabella, C; Canapè, C; Catanzaro, G; Colombo Serra, S; Jensen, PR; Karlsson, M; Lerche, MH; Miragoli, L; Poggi, L; Tedoldi, F; Uggeri, F; Venturi, L1
Brentnall, TA; Chen, R; Jung, L; Lai, LA; Pan, S; Pillarisetty, VG; Riddell, J; Sullivan, Y; Wang, L; Wong, M1
Adiseshaiah, PP; Burgan, W; Goswami, D; Guerin, TM; Kozlov, SV; McCormick, F; Mukhopadhyay, S; Nissley, DV; Yi, M1
Atri, P; Batra, SK; Bhatia, R; Cox, JL; Ganguly, K; Kaur, S; Kisling, A; Kumar, S; Mallya, K; Ram Krishn, S; Rauth, S; Shinde, D; Thomas, V; Thompson, C; Vengoji, R1
Chang, JS; Chen, HA; Chiu, CF; Hsu, TW; Lin, CY; Park, JM; Peng, JM; Saengboonmee, C; Shan, YS; Shen, YS; Su, YH1
Ahn, E; Ahn, T; Bang, S; Choi, J; Han, JM; Hwang, GS; Kim, K; Kim, Y; Lee, HS; Luo, E; Min, DS; Park, SJ; Sung, Y; Yoo, HC; Yu, YC1
Amano, H; Dash, S; Honda, M; Kawazu, M; Komuro, A; Okada, H; Ueda, T1
Cheong, JH; Hong, WC; Kang, HW; Kim, HJ; Kim, HS; Kim, JH; Kim, M; Kim, MJ; Lee, DE; Park, JS1

Reviews

1 review(s) available for glutamine and gemcitabine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

8 other study(ies) available for glutamine and gemcitabine

ArticleYear
In vivo and in vitro liver cancer metabolism observed with hyperpolarized [5-(13)C]glutamine.
    Journal of magnetic resonance (San Diego, Calif. : 1997), 2013, Volume: 232

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carbon Isotopes; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Glutaminase; Glutamine; Liver Neoplasms, Experimental; Magnetic Resonance Spectroscopy; Rats

2013
Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer.
    Scientific reports, 2017, 08-11, Volume: 7, Issue:1

    Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Diazooxonorleucine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glutamine; Humans; Metabolic Networks and Pathways; Oxidation-Reduction; Pancreatic Neoplasms; Proteomics

2017
Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.
    Cancer research, 2020, 04-15, Volume: 80, Issue:8

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutaminase; Glutamine; Heterografts; Humans; Mice; Mice, Nude; Mutation; Neoplasm Proteins; NF-E2-Related Factor 2; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras); Random Allocation; Tissue Array Analysis; Up-Regulation

2020
Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance.
    Gastroenterology, 2022, Volume: 162, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Cell Line, Tumor; Databases, Genetic; Deoxycytidine; Drug Resistance, Neoplasm; Energy Metabolism; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutaminase; Glutamine; Humans; Male; Mice, Knockout; Mice, Nude; Mucin 5AC; Pancreatic Neoplasms; Proto-Oncogene Proteins c-myc; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2022
Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer.
    Molecular metabolism, 2022, Volume: 65

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; DEAD-box RNA Helicases; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamate-Ammonia Ligase; Glutaminase; Glutamine; Humans; MicroRNAs; Pancreatic Neoplasms; Ribonuclease III; RNA, Small Interfering

2022
Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer.
    Cancer research, 2023, 03-02, Volume: 83, Issue:5

    Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamine; Humans; Hypoxia; Pancreatic Neoplasms

2023
MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
    Molecular cancer research : MCR, 2023, 05-01, Volume: 21, Issue:5

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Glutamine; Humans; Pancreatic Neoplasms

2023
SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer.
    Cells, 2023, 10-23, Volume: 12, Issue:20

    Topics: Amino Acid Transport Systems, Neutral; Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Ferroptosis; Gemcitabine; Glutamine; Humans; Mice; Pancreatic Neoplasms

2023